We are live on ! Find out more
BIOL

Biolase, Inc.
BIOL

Delisted

BIOL was delisted on the 18th of June, 2024.

Back to rankings

36 hedge funds and large institutions have $30.4M invested in Biolase, Inc. in 2016 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

56% more capital invested

Capital invested by funds: $19.5M → $30.4M (+$10.9M)

20% more funds holding

Funds holding: 30 → 36 (+6)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
36
Holders Change
+6
Holders Change %
+20%
% of All Funds
0.96%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
7
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$151K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$37.6K
3
VKH
Virtu KCG Holdings
New York
+$37.6K
4
Citadel Advisors
Citadel Advisors
Florida
+$25.1K
5
GC
Guggenheim Capital
Illinois
+$12.5K

Top Sellers

Rank Fund Capital Flow
1
PCMI
Princeton Capital Management Inc
New Jersey
-$37.6K
2
BFA
BlackRock Fund Advisors
California
-$12.5K
3
IA
IFP Advisors
Florida
-$11K
4
AIG
American International Group
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
OIM
1
Oracle Investment Management
Connecticut
$13.8M – – –
CCM
2
Camber Capital Management
Massachusetts
$6.99M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$2.09M – – –
BIT
4
BlackRock Institutional Trust
California
$1.8M – – –
BC
5
Birchview Capital
Vermont
$1.69M – – –
CCM
6
Consonance Capital Management
New York
$1.64M +$151K +12 +14%
TA
7
Teton Advisors
New York
$447K – – –
PCMI
8
Princeton Capital Management Inc
New Jersey
$394K -$37.6K -3 -11%
D.E. Shaw & Co
9
D.E. Shaw & Co
New York
$230K – – –
California Public Employees Retirement System
10
California Public Employees Retirement System
California
$163K – – –
BFA
11
BlackRock Fund Advisors
California
$134K -$12.5K -1 -11%
Morgan Stanley
12
Morgan Stanley
New York
$123K – – –
GI
13
GAMCO Investors
Connecticut
$120K – – –
Deutsche Bank
14
Deutsche Bank
Germany
$94K – – –
Northern Trust
15
Northern Trust
Illinois
$91K – – –
TMC
16
Trellus Management Company
Florida
$79K – – –
GF
17
Gabelli Funds
New York
$56K – – –
Bank of New York Mellon
18
Bank of New York Mellon
New York
$53K – – –
Goldman Sachs
19
Goldman Sachs
New York
$49K – – –
VKH
20
Virtu KCG Holdings
New York
$44K +$37.6K +3 New
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$43K +$37.6K +3 New
SBIA
22
Sheaff Brock Investment Advisors
Indiana
$37K – – –
Citadel Advisors
23
Citadel Advisors
Florida
$33K +$25.1K +2 New
Stifel Financial
24
Stifel Financial
Missouri
$26K – – –
State Street
25
State Street
Massachusetts
$24K – – –
1
2

BIOL Hedge Fund Activity: Q1 2016 in Review

36 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q1 2016, worth a combined $30.4M — up 56% from $19.5M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new BIOL positions and 1 closed out — a net gain of 6 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Consonance Capital Management, adding an estimated $151K. The largest seller was Princeton Capital Management Inc, cutting an estimated $37.6K.

  • 36 institutional investors held Biolase, Inc. (BIOL) as of Q1 2016, up from 30 in Q4 2015.
  • Funds reported $30.4M of Biolase, Inc. stock for Q1 2016, up 56% quarter-over-quarter.
  • 7 funds opened new Biolase, Inc. positions in Q1 2016 and 1 closed out, a net change of +6 holders.
  • The largest Biolase, Inc. buyer in Q1 2016 was Consonance Capital Management, an estimated $151K added.
  • The largest Biolase, Inc. seller in Q1 2016 was Princeton Capital Management Inc, an estimated $37.6K sold.

Based on aggregated 13F filings for Q1 2016.